We report a NSCLC patient with KRAS p. G12V mutation and LM who achieved 29 months of remission using intrathecal pemetrexed, thiotepa, and methotrexate via an Ommaya reservoir, combined with tislelizumab and bevacizumab. Here, KRAS is linked to non-small cell lung carcinoma.